clinical trial

[CNS Drugs] HER2-targeted therapies, including antibody-drug conjugates, have presented new therapeutic options for this patient population; however, additional data for both small-molecule inhibitors and antibody-drug conjugates with respect to patients with central nervous system metastases is needed. Scientists specifically review the data for the management of HER2+ parenchymal brain metastases.

[Lyell Immunopharma, Inc. (Globenewswire, Inc.)] Lyell Immunopharma, Inc. announced that US FDA has cleared an Investigational New Drug (IND) application to initiate a Phase I clinical trial for LYL132, an investigational T-cell receptor therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 that the company is developing in collaboration with GSK.

[Athira Pharma, Inc.] Athira Pharma, Inc. announced that patient dosing has begun in SHAPE, a Phase II clinical trial of ATH-1017 for the treatment of Parkinson's disease dementia and Dementia with Lewy bodies. ATH-1017 is a small molecule designed to enhance the activity of Hepatocyte Growth Factor and its receptor, MET, to impact neurodegeneration and regenerate brain tissue.

[Gene Therapy] The authors indicated that the IONIS 486178 antisense oligonucleotide (ASO) targeted mutant DMPK mRNAs in the brain and strongly supported the feasibility of a therapy for dystrophia myotonica type 1 patients based on the intrathecal injection of an ASO.

[New England Journal of Medicine] Scientists review new types of clinical trials to evaluate whether cytoprotective drugs can slow infarct growth prior to reperfusion and/or ameliorate the consequences of reperfusion, such as haemorrhagic transformation.

[Lyell Immunopharma, Inc.] Lyell Immunopharma, Inc. announced that the US FDA has cleared an Investigational New Drug (IND) application to initiate a Phase I clinical trial for LYL132, an investigational T-cell receptor therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 that the company is developing in collaboration with GSK.